Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, renal, metabolic, skeletal, autoimmune, and chronic inflammatory diseases. This review describes the comorbidities associated with MPNs and the potential impact of early intervention with anti-inflammatory and/or immunomodulatory agents such as JAK-inhibitors, statins, and IFN-α to inhibit cancer progression and reduce MPN-associated comorbidity impact. Early intervention may yield a subset of patients who achieve minimal residual disease, thereby likely reducing the comorbidity burden and improving the cost-effective socioeconomic profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 1×
“Ruxolitinib, the first drug in this class, has recently been approved based on the results of the two large Phase III COMFORT trials [94,95].”
BackgroundJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · cited 1×
“Ruxolitinib, the first drug in this class, has recently been approved based on the results of the two large Phase III COMFORT trials [94,95].”
BackgroundIFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368
Risks of myeloid malignancies in patients with autoimmune conditions
Anderson, L. A., Pfeiffer, R. M., Landgren, O., Gadalla, S., Berndt, S. I., & Engels, E. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604935 · Cited by 253 · cited 1×
“A modest but significant association between autoimmune or inflammatory diseases and the development of Philadelphia chromosome-negative MPNs has been documented in a large epidemiological study [42], providing further evidence that autoimmune or inflammatory diseases might be of pathogenetic importance for the develo…”
BackgroundHarrison, C. N., Mesa, R. A., Kiladjian, J., Al‐Ali, H., Gisslinger, H., Knoops, L., Squier, M., Sirulnik, A., Mendelson, E., Zhou, X., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12375 · Cited by 90 · cited 1×
“In the Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment (COMFORT)-I and COMFORT-II Phase III trials, an analysis of symptom burden of patients with MF at baseline reported similar findings [52–54].”
ResultTherapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis
Verstovsek, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2836 · Cited by 43 · cited 1×
“Various preclinical and clinical studies have shown that treatment with JAK1/JAK2 inhibitors resulted in significant spleen reduction and improvement in hypermetabolic symptoms and, accordingly, has been associated with a significant improvement in QoL [92–95].”
Background
Cited by
on behalf of the COMFORT-II Investigators, Harrison, C. N., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M. M., Sun, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.148 · Cited by 519
Koschmieder, S., Mughal, T. I., Hasselbalch, H. C., Barosi, G., Valent, P., Kiladjian, J.-J., Jeryczynski, G., Gisslinger, H., Jutzi, J. S., Pahl, H. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.12 · Cited by 161
Self-citationInflammation and myeloproliferative neoplasms
Lussana, F., & Rambaldi, A. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.010 · Cited by 136
Targeting Immune Signaling Pathways in Clonal Hematopoiesis
Azrakhsh, N. A., Mensah-glanowska, P., Sand, K., & Kittang, A. O. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190325100636 · Cited by 8
Metadata
- Authors
- Hasselbalch, H. C.
- Venue
- Expert Review of Hematology
- Publisher
- Informa UK Limited
- Published
- 2014-02-13
- Volume
- 7
- Issue
- 2
- Pages
- 203-216
- ISSN
- 1747-4086 (ISSN-L)
- 1747-4094
- OpenAlex
- W2145056924
- Cited by
- 48
- References
- 6
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. https://app.cochat.ai/papers/10.1586/17474086.2013.876356
- The paper
- Hasselbalch, H. C. (2014). Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology. https://doi.org/10.1586/17474086.2013.876356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.